Ginkgo Bioworks Holdings Inc vs Illinois Tool Works Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.4 (market cap $505.73M), while Illinois Tool Works Inc. trades at $292.1 (market cap $83.49B). The key difference: Illinois Tool Works Inc. is far larger — about 165.1× Ginkgo Bioworks Holdings Inc's market cap, and Illinois Tool Works Inc. pays a 2.35% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | ITW | |
|---|---|---|
Market Cap | $505.73M | $83.49B |
Sector | Health | Industrials |
52-Week High | $16.14 | $299.60 |
52-Week Low | $5.48 | $241.07 |
Enterprise Value | $607.68M | $92.34B |
Dividend Yield | — | 2.35% |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
ITW trades at $293.66, down 0.29% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 19.39% net income margin and 104.65% ROE, though valuations appear elevated at P/E 26.55 and P/B 28.85. Recent Q2 2026 earnings beat expectations at $2.84 EPS, and management raised full-year guidance amid manufacturing sector recovery. The company announced a 7% dividend increase and $6 billion share repurchase program in August 2026.
Outlook remains positive with analyst consensus target of $314.25 offering 7% upside potential. Key catalysts include continued manufacturing recovery and margin expansion from the 80/20 program. Risks include premium valuation concerns and potential organic sales declines masked by currency gains. Institutional sentiment is mixed with 21% buy ratings versus 32% sell recommendations.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →